A systematic review of methamphetamine precursor regulations

Addiction

Volumn 106, Issue 11, 2011, Pages 1911-1924

  McKetin, Rebecca ^a,b   Sutherland, Rachel ^b   Bright, David A ^b   Norberg, Melissa M ^b  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Amphetamine; Law enforcement; Methamphetamine; Precursors; Regulations; Substance use; Supply

Indexed keywords

CENTRAL STIMULANT AGENT; DECONGESTIVE AGENT; DESIGNER DRUG; METHAMPHETAMINE; PRODRUG; PSEUDOEPHEDRINE; STREET DRUG;

CHEMISTRY; COMMERCIAL PHENOMENA; DEVELOPING COUNTRY; DRUG ABUSE; DRUG CONTROL; HEALTH CARE QUALITY; HUMAN; LAW ENFORCEMENT; LEGAL ASPECT; METABOLISM; METHODOLOGY; NORTH AMERICA; REVIEW;

AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM STIMULANTS; COMMERCE; DESIGNER DRUGS; DEVELOPING COUNTRIES; DRUG AND NARCOTIC CONTROL; HUMANS; LAW ENFORCEMENT; METHAMPHETAMINE; NASAL DECONGESTANTS; NORTH AMERICA; PRODRUGS; PROGRAM EVALUATION; PSEUDOEPHEDRINE; STREET DRUGS;

EID: 80053583194     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2011.03582.x     Document Type: Review

References (47)

1. United Nations Office on Drugs and Crime. World Drug Report 2010. New York: United Nations; 2010.
2. United Nations Office on Drugs and Crime. World Drug Report 2007. New York: United Nations; 2007.
3. Nicosia N., Pacula R. L., Kilmer B., Lundberg R., Chiesa J. The Economic Cost of Methamphetamine Use in the United States, 2005. Santa Monica, CA: RAND Corporation; 2009.
4. Reed E. The prescription for eradicating meth labs: a call for states to enact stricter chemical control over precursors. Capital University Law Review 2009; 37: 787-818.
5. Allen A., Cantrell T. S. Synthetic reductions in clandestine amphetamine and methamphetamine laboratories-a review. Forensic Sci Int 1989; 42: 183-99.
6. Callaghan R. C., Cunningham J. K., Victor J. C., Liu L.-M. Impact of Canadian federal methamphetamine precursor and essential chemical regulations on methamphetamine-related acute-care hospital admissions. Drug Alcohol Depend 2009; 105: 185-93.
7. Cunningham J. K., Liu L.-M. Impacts of federal ephedrine and pseudoephedrine regulations on methamphetamine-related hospital admissions. Addiction 2003; 98: 1229-37.
8. Cunningham J. K., Liu L.-M. Impacts of federal precursor chemical regulations on methamphetamine arrests. Addiction 2005; 100: 479-88.
9. Cunningham J. K., Liu L.-M. Impact of methamphetamine precursor chemical legislation, a suppression policy, on the demand for drug treatment. Soc Sci Med 2008; 66: 1463-73.
10. Cunningham J. K., Liu L.-M., Muramoto M. Methamphetamine suppression and route of administration: precursor regulation impacts on snorting, smoking, swallowing and injecting. Addiction 2008; 103: 1174-86.
11. Cunningham J. K., Liu L.-M., Callaghan R. Impact of US and Canadian precursor regulation on methamphetamine purity in the United States. Addiction 2009; 104: 441-53.
12. Cunningham J. K., Bojorquez I., Campollo O., Liu L. M., Maxwell J. C. Mexico's methamphetamine precursor chemical interventions: impacts on drug treatment admissions. Addiction 2010; 105: 1973-83.
13. Reuter P., Caulkins J. P. Does precursor regulation make a difference? Addiction 2003; 98: 1177-80.
14. McKetin R. Is methamphetamine precursor regulation controlling or diverting the drug problem? Addiction 2008; 103: 521-3.
15. Cunningham J. K., Liu L.-M. Guidelines for measuring impacts of methamphetamine precursor chemical regulations: a reply to Reuter & Caulkins (2003). Addiction 2003; 98: 1463-4.
16. The Cochrane Effective Practice and Organisation of Care Review Group (EPOC). Data Collection Checklist. Ottawa: EPOC; 2002. Available at: (accessed November 2010) (Archived by Webcite® at:).
17. Zaza S., Wright-De Agüero L. K., Briss P. A., Truman B. I., Hopkins D. P., Hennessy M. H. etal. Data collection instrument and procedure for systematic reviews in the Guide to Community Preventive Services. Task Force on Community Preventive Services. Am J Prev Med 2000; 18: 44-74.
18. Brandenburg M. A., Brown S. J., Arneson W. L., Arneson D. L. The association of pseudoephedrine sales restrictions on emergency department urine drug screen results in Oklahoma. J Oklahoma State Med Assoc 2007; 100: 436-9.
19. Dobkin C., Nicosia N. The war on drugs: methamphetamine, public health, and crime. Am Econ Rev 2009; 99: 324-49.
20. Nonnemaker J., Engelen M., Shive D. Are methamphetamine precursor control laws effective tools to fight the methamphetamine epidemic? Health Econ 2010; 20: 519-31.
21. Crime and Misconduct Commission. Illicit Drug Markets in Queensland: A Strategic Assessment. Brisbane: Crime and Misconduct Commission; 2010. Available at: (accessed October 2010) (Archived by Webcite® at:).
22. Office of National Drug Control Policy. Pushing Back Against Meth: A Progress Report on the Fight Against Methamphetamine in the United States. Washington, DC: Executive Office of the President of the United States; 2006.
23. Berbatis C. G., Sunderland V. B., Dhaliwal S. S. Linked electronic medication systems in community pharmacies for preventing pseudoephedrine diversion: a review of international practice and analysis of results in Australia. Drug Alcohol Rev 2009; 28: 586-91.
24. Burke B. A., Lewis R. W., Latenser B. A., Chung J. Y., Willoughby C. Pseudoephedrine legislation decreases methamphetamine laboratory-related burns. J Burn Care Res 2008; 29: 138-40.
25. Borders T. F., Booth B. M., Han X., Wright P., Leukefeld C., Falck R. S. etal. Longitudinal changes in methamphetamine and cocaine use in untreated rural stimulant users: racial differences and the impact of methamphetamine legislation. Addiction 2008; 103: 800-8.
26. Chintalova-Dallas R., Case P., Kitsenko N., Lazzarini Z. Boltushka: a homemade amphetamine-type stimulant and HIV risk in Odessa, Ukraine. Int J Drug Policy 2009; 20: 347-51.
27. Sudakin D., Power L. E. Regional and temporal variation in methamphetamine-related incidents: applications of spatial and temporal scan statistics. Clin Toxicol (PA) 2009; 47: 243-7.
28. Sloboda Z., Kozel N., McKetin R. Use of archival data. In: Sloboda Z., editor. Epidemiology of Drug Abuse. New York: Springer Press; 2005, p. 63-78.
29. Chemical Diversion and Trafficking Act of 1988, Pub. L. 100-690, Vol. 102 Stat. 4181, 18 November 1988. Washington, DC: Office of the Federal Register.
30. Records, reports, imports, and exports of precursor and essential chemicals, tableting machines and encapsulating machines. Final rule. 1 August 1989. Fed Regist 1989; 54: 31657-69.
31. Domestic Chemical Diversion Control Act of 1993, Pub. L. 103-200 Vol. 107 Stat. 2333, 17 December 1993. Washington, DC: Office of the Federal Register.
32. Implementation of the Domestic Chemical Diversion Control Act of 1993 (PL 103-200). Final Rule. Fed Regist 1995; 60: 32447-65.
33. Comprehensive Methamphetamine Control Act of 1996, Pub. L. 104-237, Vol. 110 Stat. 3099, 3 October 1996. Washington, DC: Office of the Federal Register.
34. Implementation of the Comprehensive Methamphetamine Control Act of 1996; Regulation of pseudoephedrine, phenylpropanolamine, and combination ephedrine drug products and reports of certain transactions to nonregulated persons. Proposed Rules. Fed Regist 1997; 62: 52294-303.
35. Gonzales R., Mooney L., Rawson R. A. The methamphetamine problem in the United States. Annu Rev Public Health 2010; 31: 385-98.
36. Methamphetamine Anti-Proliferation Act of 2000, Pub. L. 106-310, 114 Stat. 1101, 17 October 2000. Washington, DC: Office of the Federal Register.
37. Implementation of the Methamphetamine Anti-Proliferation Act; Thresholds for retailers and for distributors required to submit mail order reports; Changes to mail order reporting requirements. Final Rule. Fed Regist 2003; 68: 57799-804.
38. House Bill No. 2176. Oklahoma Session Laws 59, 2004. Trooper Nik Green, Rocky Eales and Matthew Evans Act. The Oklahoma State Courts Network: Oklahoma; 2004.
39. House Bill No. 164. House of Representatives. Seventy-Ninth Legislature, 2005. An Act Relating to the Civil and Criminal Consequences of Engaging in Conduct Related to the Manufacture of Methamphetamine and to the Distribution and Retail Sales of Certain Chemical Substances. Austin: State of Texas; 2005.
40. Government of Canada. Controlled drugs and substances act: precursor control regulations (SOR/2002-359). Canada Gazette 2002; 136: 2139-200. Available at: (accessed October 2010) (Archived by Webcite® at:).
41. Royal Canadian Mounted Police. Drug Situation Report 2005. Canada: Royal Canadian Mounted Police; 2005, Available at: (accessed December 2010) (Archived by Webcite® at:).
42. Ley Federal Para El Control De Precursores Químicos, Productos Químicos Esenciales Y Máquinas Para Elaborar Cápsulas, Tabletas Y/O Comprimidos. [Federal law for the control of chemical precursors, essential chemical products and machines to produce capsules, tablets and/or pills]. Diario Oficial, 26 December 1997; p. 1-8.
43. Consejo de Salubridad General. Acuerdo por el que se establecen medidas de protección en material de salud humana para prevenir el uso y consumo de pseudoefedrina y efedrina. [General Health Council. Agreement establishing protective measures for human health to prevent the use and consumption of pseudoephedrine and ephedrine]. Diario Oficial, 13 June 2008; p. 31-3.
44. McKetin R., Murtagh V. Importation and domestic production of methamphetamine. In: McKetin R., McLaren M., Kelly E., editors. The Sydney Methamphetamine Market: Patterns of Supply, Use, Personal Harms and Social Consequences. National Drug Law Enforcement Research Fund Monograph Series No. 13.Adelaide, Australia: Australian Centre for Policing Research, Commonwealth of Australia; 2005, p. 25-37.
45. McCain L. J., McCleary R. The statistical analysis of the simple interrupted time-series quasi-experiment. In: Cook T. D., Campbell D. T., editors. Quasi-Experimentation. Design and Analysis Issues for Field Settings. Boston: Houghton Mifflin Company; 1979, p. 233-94.
46. Winstock A. R., Marsden J., Mitcheson L. What should be done about mephedrone? BMJ 2010; 340: c1605.
47. Uchiyama N., Kikura-Hanajiri R., Kawahara N., Goda Y. [Analysis of designer drugs detected in the products purchased in fiscal year 2006]. Yakugaku Zasshi 2008; 128: 1499-505.